



(51) International Patent Classification:

A61K 39/02 (2006.01) A61P 37/08 (2006.01)
A61K 39/085 (2006.01) A61P 31/00 (2006.01)
C07K 16/12 (2006.01)

(21) International Application Number:

PCT/SG2016/050013

(22) International Filing Date:

12 January 2016 (12.01.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201500223V 12 January 2015 (12.01.2015) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY
AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10
Connexis, Singapore 138632 (SG).

(72) Inventors: WANG, Yue; c/o Institute of Molecular and
Cell Biology, 61 Biopolis Drive, Singapore 138673 (SG).
HUANG, Zhenxing; c/o Institute of Molecular and Cell
Biology, 61 Biopolis Drive, Singapore 138673 (SG).

(74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD;
P.O. Box 1531, Robinson Road Post Office, Singapore
903031 (SG).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TA, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: MONOCLONAL ANTIBODY AGAINST MURAMYL PEPTIDES IN PREVENTION AND TREATMENT OF IMMUNE-MEDIATED DISEASES




Fig. 7

(57) Abstract: Disclosed are methods of treating an autoimmune or inflammatory disease using a composition comprising an isolated antibody or an antigen-binding fragment or variant thereof that is capable of binding to muramyl peptide, derivative, analog or salt thereof, wherein said muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid and a salt thereof. In one preferred embodiment, the composition can comprise of the isolated antibody or an antigen-binding fragment and one or more therapeutic agents such as Tumor Necrosis Factor (TNF) inhibitor. The autoimmune or inflammatory disease is selected from a group consisting of sepsis, septic shock, Crohn's disease, rheumatoid arthritis, asthma, allergy, atopic disorders, multiple sclerosis, pertussis, gonorrhea, inflammatory bowel disease, and antibiotic associated disorder.